The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

This Phase II, randomized, double-blind, placebo-controlled dose-ranging, parallel and adaptive study aims to evaluate the efficacy and safety of enpatoran in SLE and in CLE (SCLE and/or DLE) participants receiving standard of care (WILLOW).

To Learn More Contact:

EMD Serono US Medical Information at 888-275-7376 or email at eMediUSA@emdserono.com

Communications Center by phone at +49 6151 72 5200 or email at service@emdgroup.com.

ClinicalTrials.gov identifier (NCT number): NCT05162586